Pascolizumab (SB-240683) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for the research of asthma.In Vitro:Pascolizumab binding of IL-4 inhibits IL-4 interaction with the alpha chain of the IL-4 receptor.
Pascolizumab (0-10000 pM; 3 days) shows anti-proliferative activity with IC50 values of 157, 377 pM for T-cell and Tonsil B-cell, respectively.